Gilead Sciences (GILD) 10-K Summary — Year Ended Dec 31, 2024

Gilead Sciences' annual 10-K filing reports a revenue increase and positive profitability. The supplied data includes financial metrics but does not contain the full text of business overview or risk factors sections.

Key takeaway

Year ended Dec 31, 2024 · FY2025 10-K

Financial snapshot

Selected annual figures reported with the filing, shown separately from the narrative summary.

Annual revenue

$28.8B

Revenue reported for the fiscal year.

Operating income

$1.7B

Income from operations reported for the year.

Net income

$480M

Net income reported for the year.

Operating cash flow

$10.8B

Cash generated by operating activities.

Annual revenue trend

Reported annual revenue and its change from the preceding fiscal year.

Period ended	Revenue	Year-over-year change
Dec 31, 2021	$27.3B	n/a
Dec 31, 2022	$27.3B	-0.1%
Dec 31, 2023	$27.1B	-0.6%
Dec 31, 2024	$28.8B	+6.0%

Business overview

The supplied data does not include a description of the company's business; the filing references Item 1 Business but the text is not provided. Only the company name and filing metadata are available.

Financial performance

Revenue increased compared to the prior year. Operating income and net income were both positive, with net income significantly lower than operating income. Operating cash flow was strong.

Material risks

The filing references Item 1A Risk Factors but the specific risk descriptions are not included in the supplied data. No material risks can be identified from the provided context.

Liquidity and capital

The filing references a section on Liquidity and Capital Resources but does not include its content. The supplied metrics indicate a strong operating cash flow, suggesting sufficient liquidity.

What to watch

Monitor the revenue trend in the next filing, given the reported increase.